(ANSAmed) - TEL AVIV, FEBRUARY 15 - A 94 percent decrease in symptomatic cases of Covid was detected among those who were immunized with the Pfizer vaccine.
This was revealed by a research conducted by the Israeli health fund Clalit, thus confirming similar results previously collected by the Maccabi health fund.
Clalit - says today's press - collected data from 1.2 million Israelis, only half of whom had been vaccinated. It was thus found that the greatest efficacy of the vaccine is recorded starting one week after the administration of the second dose. The decline in Covid symptomatic cases - the Jerusalem Post specifies - is then 94 percent and the drop in severe cases of the disease is 92 percent. The efficacy of the vaccine remains high in all age groups aged 16 and over, including the over 70s.
Meanwhile, the ministry of health has updated that 3.9 million Israelis (out of a total of over nine million) have so far received a first dose of the vaccine. Of these, 2.5 million also received the second dose. (ANSAmed).
